Gilead Sciences (GILD) Shares are Down -1.52%

Gilead Sciences (GILD) has risen sharply, recording gains of 0.38% in the past 4 weeks. However, the stock has corrected -1.52% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 0.59% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 0.36% and the fifty day Moving Average is 3.37%. Gilead Sciences Inc. has dropped 6.53% during the last three month period . Year-to-Date the stock performance stands at -20.34%.

Gilead Sciences (GILD) : 12 investment research analysts covering Gilead Sciences (GILD) have an average price target of $108.92 for the near short term. The highest target price given by the Brokerage Firm to the stock is $122 and the lowest target is $93 for the short term. Analysts expect the variance to be within $8.82 of the average price.


Gilead Sciences (NASDAQ:GILD): On Fridays trading session , Opening price of the stock was $80.11 with an intraday high of $80.33. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $79.27. However, the stock managed to close at $79.77, a loss of 0.39% for the day. On the previous day, the stock had closed at $80.08. The total traded volume of the day was 8,928,026 shares.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.